Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
SINOPEC CORP
00386
5
SHANGHAI PECHEM
00338
CN Stock MarketDetailed Quotes
Pacific Shuanglin Bio-pharmacy (000403)
- 11.00
- -0.20-1.79%
Trading May 18 10:10 CST
10.45BMarket Cap29.57P/E (TTM)
11.20High10.99Low27.66KlotVolume11.16Open11.20Prev Close30.57MTurnover0.29%Turnover Ratio24.94P/E (Static)950.40MShares19.1352wk High1.29P/B10.35BFloat Cap10.9952wk Low12.32Limit Up940.68MShs Float38.06Historical High10.08Limit Down1.88%Range %0.12Historical Low0.27Dividend TTM11.05Avg Price13.13KlotAsk2.45%Div Yield TTM100Lot Size14.31KlotBid
Pacific Shuanglin Bio-pharmacy (000403) Income Statement
All
YOY
| (Q1)Mar 31, 2026 | (FY)Dec 31, 2025 | (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | -8.47%342.92M | -0.83%2.63B | -14.40%1.62B | -13.18%986.48M | -14.00%374.65M | 14.00%2.65B | 37.49%1.89B | 60.23%1.14B | 67.00%435.64M | -3.18%2.33B |
| Operating revenue | -8.47%342.92M | -0.83%2.63B | -14.40%1.62B | -13.18%986.48M | -14.00%374.65M | 14.00%2.65B | 37.49%1.89B | 60.23%1.14B | 67.00%435.64M | -3.18%2.33B |
| Other operating revenue | ---- | 8.62%1.14M | ---- | -27.19%465.58K | ---- | -67.93%1.05M | ---- | -74.34%639.45K | ---- | -65.97%3.27M |
| Total operating cost | 14.46%316.47M | 11.22%2.02B | -5.90%1.2B | -7.84%711.56M | -7.06%276.48M | 10.75%1.82B | 23.84%1.28B | 34.90%772.12M | 36.27%297.49M | -6.49%1.64B |
| Operating cost | 14.86%223.5M | 13.98%1.54B | -7.13%868.65M | -8.70%516.64M | -8.06%194.59M | 19.52%1.35B | 36.21%935.38M | 55.70%565.85M | 57.26%211.64M | -1.87%1.13B |
| Operating tax surcharges | 47.98%6.17M | 0.86%22.26M | -5.30%14.64M | -3.76%9.11M | -8.12%4.17M | 1.73%22.07M | 32.01%15.46M | 42.75%9.47M | 61.35%4.54M | 29.15%21.69M |
| Operating expense | 42.88%45.68M | -0.56%243.23M | -5.10%179.07M | -8.27%94.48M | -5.85%31.97M | -14.34%244.6M | -6.71%188.69M | -14.89%102.99M | -18.05%33.96M | -28.53%285.57M |
| Administration expense | -16.25%38.32M | 1.18%194.94M | 5.70%138.55M | 9.10%92.88M | 14.54%45.75M | 6.88%192.65M | 7.75%131.08M | 4.70%85.13M | 2.78%39.94M | 8.93%180.25M |
| Financial expense | 25.58%-7.54M | 26.63%-36.08M | 25.11%-27.67M | 18.47%-20.35M | 24.75%-10.13M | 14.59%-49.17M | 13.78%-36.95M | 15.10%-24.95M | 1.42%-13.46M | -4.08%-57.57M |
| -Interest expense (Financial expense) | 39.54%4.92M | 70.42%18.19M | 66.57%12.8M | 28.39%7.04M | 75.52%3.53M | 10.90%10.67M | 24.02%7.68M | 22.50%5.48M | -18.25%2.01M | -19.96%9.63M |
| -Interest Income (Financial expense) | 8.81%-12.5M | 9.46%-54.57M | 9.37%-40.74M | 10.42%-27.5M | 12.66%-13.71M | 10.95%-60.27M | 10.67%-44.95M | 9.92%-30.7M | 4.55%-15.69M | -3.84%-67.68M |
| Research and development | 2.07%10.34M | 1.35%55.92M | -32.76%30.91M | -44.11%18.8M | -51.47%10.13M | -30.76%55.18M | -14.48%45.98M | 14.52%33.64M | 46.17%20.86M | 5.73%79.69M |
| Credit Impairment Loss | -66.58%1.93M | -301.18%-9.36M | -87.50%357.35K | -46.96%991.89K | 301.51%5.79M | 44.90%4.65M | -64.56%2.86M | -79.15%1.87M | -88.05%1.44M | 127.17%3.21M |
| Asset Impairment Loss | ---- | -7,880.92%-100.05M | ---1.22M | ---1.22M | ---- | ---1.25M | ---- | ---- | ---- | ---- |
| Other net revenue | -54.48%5.33M | -307.86%-85.96M | -37.90%17.47M | -41.40%10.81M | 6.75%11.7M | 593.92%41.36M | -9.54%28.13M | -25.16%18.44M | -46.86%10.96M | -48.51%5.96M |
| Fair value change income | 58.60%-975.78K | -32.67%4.3M | 45.21%-5.8M | 54.56%-6.23M | 44.39%-2.36M | 133.64%6.38M | -218.38%-10.59M | -342.28%-13.7M | -254.95%-4.24M | -484.85%-18.97M |
| Invest income | -49.14%3.02M | -49.53%8.95M | -45.22%16.1M | -43.71%13.72M | -31.23%5.95M | 139.64%17.74M | 574.51%29.39M | 839.73%24.37M | 1,301.96%8.65M | 143.66%7.4M |
| Asset deal income | -215.63%-18.28K | 735.96%756K | 1,217.05%764.81K | 14.89%785.81K | -97.34%15.81K | 78.19%-118.88K | 382.99%58.07K | 5,588.70%683.96K | 110,562.94%595.4K | -224.40%-544.96K |
| Other revenue | -41.00%1.36M | -32.33%9.44M | 13.41%7.27M | -47.08%2.76M | -48.89%2.31M | -6.08%13.96M | -33.96%6.41M | -29.62%5.21M | -13.31%4.52M | -0.01%14.86M |
| Operating profit | -71.07%31.78M | -40.11%527.21M | -32.45%431.46M | -25.30%285.73M | -26.32%109.87M | 26.63%880.31M | 71.41%638.75M | 137.04%382.5M | 136.04%149.11M | 4.79%695.19M |
| Add:Non operating Income | -54.56%4.49K | 247.02%2.22M | -77.31%24.03K | -87.60%12.24K | -90.84%9.88K | -81.89%639.61K | -96.77%105.9K | -90.82%98.68K | 56,550.50%107.88K | 40.42%3.53M |
| Less:Non operating expense | -58.44%2.71M | 3.39%29.13M | 27.12%24.55M | 43.14%16.81M | -21.24%6.51M | 165.53%28.17M | 230.11%19.31M | 277.66%11.74M | 3,121.51%8.27M | 91.09%10.61M |
| Total profit | -71.87%29.08M | -41.33%500.3M | -34.32%406.94M | -27.48%268.93M | -26.67%103.36M | 23.93%852.78M | 67.41%619.55M | 132.76%370.85M | 124.03%140.95M | 4.20%688.11M |
| Less:Income tax cost | -56.01%6.34M | -25.03%80.77M | -35.62%49.44M | -24.76%33.01M | -24.41%14.42M | 40.58%107.74M | 73.51%76.79M | 168.72%43.88M | 184.83%19.08M | 5.41%76.64M |
| Net profit | -74.44%22.73M | -43.69%419.54M | -34.13%357.5M | -27.85%235.92M | -27.02%88.94M | 21.84%745.04M | 66.59%542.76M | 128.65%326.98M | 116.78%121.87M | 4.05%611.47M |
| Net profit from continuing operation | -74.44%22.73M | -43.69%419.54M | -34.13%357.5M | -27.85%235.92M | -27.02%88.94M | 21.84%745.04M | 66.59%542.76M | 128.65%326.98M | 116.78%121.87M | 4.05%611.47M |
| Less:Minority Profit | -58.54%-237.29K | 196.76%269.57K | 1,139.25%316.2K | 1,542.85%123.94K | -89.81%-149.67K | 56.37%-278.61K | 106.68%25.52K | 93.69%-8.59K | 50.02%-78.85K | -214.31%-638.57K |
| Net profit of parent company owners | -74.22%22.97M | -43.75%419.27M | -34.19%357.18M | -27.89%235.79M | -26.95%89.09M | 21.76%745.32M | 66.38%542.73M | 128.44%326.98M | 116.31%121.95M | 4.25%612.11M |
| Earning per share | ||||||||||
| Basic earning per share | -77.78%0.02 | -43.59%0.44 | -33.33%0.38 | -26.47%0.25 | -47.06%0.09 | -7.14%0.78 | 27.80%0.57 | 73.65%0.34 | 120.49%0.17 | 4.54%0.84 |
| Diluted earning per share | -77.78%0.02 | -43.59%0.44 | -33.33%0.38 | -26.47%0.25 | -47.06%0.09 | -7.14%0.78 | 27.80%0.57 | 73.65%0.34 | 120.49%0.17 | 4.58%0.84 |
| Other composite income | -1,309.24%-9.97K | -274.79%-13.44K | -23.24%-6.95K | -173.32%-2.54K | -169.74%-707.31 | -30.35%7.69K | -126.87%-5.64K | -86.47%3.46K | 111.10%1.01K | -69.03%11.04K |
| Other composite income of parent company owners | -1,309.24%-9.97K | -274.79%-13.44K | -23.24%-6.95K | -173.32%-2.54K | -169.74%-707.31 | -30.35%7.69K | -126.87%-5.64K | -86.47%3.46K | 111.10%1.01K | -69.03%11.04K |
| Total composite income | -74.45%22.72M | -43.69%419.52M | -34.13%357.49M | -27.85%235.91M | -27.02%88.94M | 21.84%745.05M | 66.57%542.75M | 128.61%326.98M | 116.82%121.87M | 4.04%611.48M |
| Total composite income of parent company owners | -74.23%22.96M | -43.75%419.25M | -34.19%357.17M | -27.89%235.79M | -26.95%89.09M | 21.76%745.33M | 66.37%542.73M | 128.40%326.99M | 116.35%121.95M | 4.25%612.12M |
| Total composite income of minority owners | -58.54%-237.29K | 196.76%269.57K | 1,139.25%316.2K | 1,542.85%123.94K | -89.81%-149.67K | 56.37%-278.61K | 106.68%25.52K | 93.69%-8.59K | 50.02%-78.85K | -214.31%-638.57K |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
| Auditor | -- | KPMG Huazhen Certified Public Accountants (Special General Partnership) | -- | -- | -- | KPMG Huazhen Certified Public Accountants (Special General Partnership) | -- | -- | -- | KPMG Huazhen Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Market Insights
Hot Topics Hot Topics
Middle East conflict spreads to the stock market! How should investors respond?
According to Axios, on Sunday local time, Trump rejected Iran's latest ceasefire proposal, prompting a sharp response from Iran: no one woul
牛牛課堂
Mar 4 17:09
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
牛牛課堂
Mar 18 18:18
Hormuz, Term Structure and USO: Navigating the Energy Storm